BRPI0921888A2 - terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase - Google Patents

terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase

Info

Publication number: BRPI0921888A2
Authority: BR; Brazil
Prior art keywords: inhibitor; combination therapy; egfr; kinase; kinase inhibitor
Prior art date: 2008-11-11

Application number

BRPI0921888A

Other languages

English (en)

Inventor

Sandaruwan Geeganage

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-11

Filing date

2009-11-04

Publication date

2015-12-29

2009-11-04 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-12-29 Publication of BRPI0921888A2 publication Critical patent/BRPI0921888A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0921888A 2008-11-11 2009-11-04 terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase BRPI0921888A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11327608P	2008-11-11	2008-11-11
PCT/US2009/063189 WO2010056575A1 (en)	2008-11-11	2009-11-04	P70 s6 kinase inhibitor and egfr inhibitor combination therapy

Publications (1)

Publication Number	Publication Date
BRPI0921888A2 true BRPI0921888A2 (pt)	2015-12-29

Family

ID=41664868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921888A BRPI0921888A2 (pt)	2008-11-11	2009-11-04	terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase

Country Status (11)

Country	Link
US (1)	US8334293B2 (pt)
EP (1)	EP2355821A1 (pt)
JP (1)	JP2012508240A (pt)
KR (1)	KR20110075015A (pt)
CN (1)	CN102209538B (pt)
AU (1)	AU2009314336B2 (pt)
BR (1)	BRPI0921888A2 (pt)
CA (1)	CA2743295A1 (pt)
EA (1)	EA018624B1 (pt)
MX (1)	MX2011005002A (pt)
WO (1)	WO2010056575A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX370448B (es) *	2013-03-11	2019-12-13	Merck Patent Gmbh	Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa.
US20140255471A1 (en)	2013-03-11	2014-09-11	Wake Forest University Health Sciences	Method of treating brain tumors
US9457019B2 (en) *	2013-11-07	2016-10-04	Deciphera Pharmaceuticals, Llc	Methods for inhibiting tie-2 kinase useful in the treatment of cancer
CN106456774A (zh) *	2014-04-04	2017-02-22	阿斯利康(瑞典)有限公司	Nras突变的癌症的治疗中使用的egfr抑制剂及mek抑制剂的组合
CN111655243A (zh)	2018-01-29	2020-09-11	乔纳森·萨克纳-伯恩斯坦	在人类神经系统疾病中调节多巴胺的方法
DE102018205152A1 (de)	2018-04-05	2019-10-10	Glatt Ingenieurtechnik Gmbh	Verfahren und Reaktor zur Herstellung von Partikeln

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69522717T2 (de)	1995-03-30	2002-02-14	Pfizer Inc., New York	Chinazolinderivate
AU2005249380C1 (en) *	2004-04-23	2012-09-20	Exelixis, Inc.	Kinase modulators and methods of use
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2005322085B2 (en) *	2004-12-28	2012-07-19	Exelixis, Inc.	[1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US8628931B2 (en) *	2005-10-18	2014-01-14	George Mason Intellectual Properties, Inc.	mTOR pathway theranostic
AR064416A1 (es) *	2006-12-21	2009-04-01	Cancer Rec Tech Ltd	Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru)	2007-05-11	2012-08-10	Елі Ліллі Енд Компані	ИНГИБИТОРЫ р70 S6-КИНАЗЫ

2009
- 2009-11-04 MX MX2011005002A patent/MX2011005002A/es not_active Application Discontinuation
- 2009-11-04 CN CN2009801448775A patent/CN102209538B/zh not_active Expired - Fee Related
- 2009-11-04 EP EP09752049A patent/EP2355821A1/en not_active Withdrawn
- 2009-11-04 BR BRPI0921888A patent/BRPI0921888A2/pt not_active IP Right Cessation
- 2009-11-04 WO PCT/US2009/063189 patent/WO2010056575A1/en active Application Filing
- 2009-11-04 KR KR1020117010621A patent/KR20110075015A/ko active IP Right Grant
- 2009-11-04 US US13/126,484 patent/US8334293B2/en not_active Expired - Fee Related
- 2009-11-04 JP JP2011535633A patent/JP2012508240A/ja not_active Withdrawn
- 2009-11-04 AU AU2009314336A patent/AU2009314336B2/en not_active Expired - Fee Related
- 2009-11-04 EA EA201170682A patent/EA018624B1/ru not_active IP Right Cessation
- 2009-11-04 CA CA2743295A patent/CA2743295A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8334293B2 (en)	2012-12-18
CN102209538B (zh)	2013-06-12
AU2009314336A1 (en)	2010-05-20
US20110207752A1 (en)	2011-08-25
EA018624B1 (ru)	2013-09-30
KR20110075015A (ko)	2011-07-05
EA201170682A1 (ru)	2011-10-31
CA2743295A1 (en)	2010-05-20
EP2355821A1 (en)	2011-08-17
CN102209538A (zh)	2011-10-05
AU2009314336B2 (en)	2013-09-12
WO2010056575A1 (en)	2010-05-20
MX2011005002A (es)	2011-05-25
JP2012508240A (ja)	2012-04-05

Publication	Publication Date	Title
CY2020023I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
CY2019027I1 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
CY2019009I2 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
BRPI0811212A2 (pt)	2014-10-29	Inibidores de p70 quinase
ATE522535T1 (de)	2011-09-15	Pyrrolotriazin-kinasehemmer
BRPI0910668A2 (pt)	2019-09-24	inibidores de proteína quinases
BRPI0817843A2 (pt)	2015-04-07	Inibidores da quinase c-fms
BRPI0810086A2 (pt)	2016-07-26	inibidores de tirosina quinase de bruton
BRPI1009112A2 (pt)	2016-03-01	inibidores de tirosina quinase de bruton
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI1011129A2 (pt)	2016-11-01	métodos e compostos inibidores de janus cinase
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0921916A2 (pt)	2015-12-29	inibidores de akt e p70 s6 quinase
DK2116775T3 (da)	2013-02-04	Kogesektion
BRPI0918564A2 (pt)	2015-12-01	inibidores
DK2318378T3 (da)	2013-11-18	Quinazolin-derivater
BRPI0921509A2 (pt)	2016-03-08	inibidor triazolotiadiazol de proteína quinase c-met
BRPI0716198A2 (pt)	2013-11-12	Pirrolo-isoquinolinas como inibidores de cinase
BRPI0921888A2 (pt)	2015-12-29	terapia de combinação de inibidor de egfr inibidor da p70 s6 quinase
DE112009004416A5 (de)	2012-06-21	Kombinationsleuchte
DK2170891T3 (da)	2011-12-12	Pyrazolopyrimidinon-kinasehæmmere
ITTO20080468A1 (it)	2009-12-17	Termoconvettore

Legal Events

Date	Code	Title	Description
2016-07-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A E 6A ANUIDADES.
2016-11-01	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.